Borecki D, Vilsendorf I, Fabian J, Lehr M
Med Chem. 2024; 20(10):969-985.
PMID: 39041279
DOI: 10.2174/0115734064320241240709114041.
Soliman A, Elimam D, El-Senduny F, Alossaimi M, Alamri M, Bar F
J Enzyme Inhib Med Chem. 2023; 38(1):2187327.
PMID: 36912259
PMC: 10013213.
DOI: 10.1080/14756366.2023.2187327.
Mangini M, DAngelo R, Vinciguerra C, Payre C, Lambeau G, Balestrieri B
Front Cell Dev Biol. 2022; 10:966950.
PMID: 36105351
PMC: 9467450.
DOI: 10.3389/fcell.2022.966950.
El-Sayed N, Almaneai N, Ben Bacha A, El-Ashrey M, Al-Zaben M, Almarhoon Z
ACS Omega. 2022; 7(22):18443-18458.
PMID: 35694504
PMC: 9178606.
DOI: 10.1021/acsomega.2c00812.
Psarra A, Theodoropoulou M, Erhardt M, Mertiri M, Mantzourani C, Vasilakaki S
Biomolecules. 2021; 11(2).
PMID: 33668480
PMC: 7918003.
DOI: 10.3390/biom11020275.
Structural and Functional Aspects of Targeting the Secreted Human Group IIA Phospholipase A.
Kim R, Chen Z, Mann T, Bastard K, Scott K, Church W
Molecules. 2020; 25(19).
PMID: 32998383
PMC: 7583969.
DOI: 10.3390/molecules25194459.
Computational investigations of physicochemical, pharmacokinetic, toxicological properties and molecular docking of betulinic acid, a constituent of Corypha taliera (Roxb.) with Phospholipase A2 (PLA2).
Khan M, Nahar N, Rashid R, Chowdhury A, Rashid M
BMC Complement Altern Med. 2018; 18(1):48.
PMID: 29391000
PMC: 5795847.
DOI: 10.1186/s12906-018-2116-x.
Small Peptides Able to Suppress Prostaglandin E₂ Generation in Renal Mesangial Cells.
Vasilakaki S, Pastukhov O, Mavromoustakos T, Huwiler A, Kokotos G
Molecules. 2018; 23(1).
PMID: 29342835
PMC: 6017359.
DOI: 10.3390/molecules23010158.
Scalaradial Is a Potent Inhibitor of Transient Receptor Potential Melastatin 2 (TRPM2) Ion Channels.
Starkus J, Poerzgen P, Layugan K, Kawabata K, Goto J, Suzuki S
J Nat Prod. 2017; 80(10):2741-2750.
PMID: 29019677
PMC: 6687308.
DOI: 10.1021/acs.jnatprod.7b00515.
Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations.
Vasilakaki S, Barbayianni E, Leonis G, Papadopoulos M, Mavromoustakos T, Gelb M
Bioorg Med Chem. 2016; 24(8):1683-95.
PMID: 26970660
PMC: 5292099.
DOI: 10.1016/j.bmc.2016.02.040.
Inhibition of sPLA₂-IIA prevents LPS-induced neuroinflammation by suppressing ERK1/2-cPLA₂α pathway in mice cerebral cortex.
Xiang Y, Chen L, Liu H, Liu X, Wei X, Sun B
PLoS One. 2013; 8(10):e77909.
PMID: 24130900
PMC: 3793966.
DOI: 10.1371/journal.pone.0077909.
Selective inhibition of human group IIA-secreted phospholipase A2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes.
Lee L, Bryant K, Bouveret R, Lei P, Duff A, Harrop S
J Biol Chem. 2013; 288(21):15269-79.
PMID: 23482564
PMC: 3663547.
DOI: 10.1074/jbc.M112.397893.
An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats.
Iyer A, Lim J, Poudyal H, Reid R, Suen J, Webster J
Diabetes. 2012; 61(9):2320-9.
PMID: 22923652
PMC: 3425408.
DOI: 10.2337/db11-1179.
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.
Dennis E, Cao J, Hsu Y, Magrioti V, Kokotos G
Chem Rev. 2011; 111(10):6130-85.
PMID: 21910409
PMC: 3196595.
DOI: 10.1021/cr200085w.
sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model.
Wei Y, Epstein S, Fukuoka S, Birmingham N, Li X, Asbell P
Invest Ophthalmol Vis Sci. 2011; 52(7):4780-8.
PMID: 21519031
PMC: 3175946.
DOI: 10.1167/iovs.10-6350.
Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.
Coulthard L, Costello J, Robinson B, Shiels I, Taylor S, Woodruff T
Arthritis Res Ther. 2011; 13(2):R42.
PMID: 21401925
PMC: 3132024.
DOI: 10.1186/ar3278.
Inhibition of secreted phospholipases A₂ by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations.
Mouchlis V, Magrioti V, Barbayianni E, Cermak N, Oslund R, Mavromoustakos T
Bioorg Med Chem. 2011; 19(2):735-43.
PMID: 21216150
PMC: 3050527.
DOI: 10.1016/j.bmc.2010.12.030.
Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor.
Mouchlis V, Mavromoustakos T, Kokotos G
J Comput Aided Mol Des. 2010; 24(2):107-15.
PMID: 20130961
DOI: 10.1007/s10822-010-9319-7.
Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis.
Cassidy C, Setzer W
J Mol Model. 2009; 16(2):311-26.
PMID: 19603203
DOI: 10.1007/s00894-009-0547-5.
Differential expression of sPLA2 following spinal cord injury and a functional role for sPLA2-IIA in mediating oligodendrocyte death.
Titsworth W, Cheng X, Ke Y, Deng L, Burckardt K, Pendleton C
Glia. 2009; 57(14):1521-37.
PMID: 19306380
PMC: 4461868.
DOI: 10.1002/glia.20867.